Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023
- Curis, Inc. will release its third quarter 2023 financial results on November 2, 2023.
- None.
To access the live conference call, please dial (888)-390-0546 from the United States or (416)-764-8688 from other locations, shortly before 8:30 a.m. ET. The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section. A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.
About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with hematologic malignancies, such as non-Hodgkin's lymphoma and other B cell malignancies in combination with the BTK inhibitor ibrutinib, and as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with acute myeloid leukemia and myelodysplastic syndrome, for which it has received Orphan Drug Designation from the
View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-release-third-quarter-2023-financial-results-and-hold-conference-call-on-november-2-2023-301968409.html
SOURCE Curis, Inc.
FAQ
When will Curis, Inc. release its third quarter 2023 financial results?
What time is the conference call for Curis, Inc.'s financial results?
How can I access the live conference call for Curis, Inc.'s financial results?